Abstract
An orphan disease refers to a disease with a low prevalence of less than 6.5–10 cases in 10,000 people. The National Organization for Rare Disorders (NORD) and Orphanet are the organizations working for the welfare of people with orphan diseases. Orphan drugs are defined as the drugs used for the diagnosis, prevention, or treatment of orphan diseases. The US-FDA provides a list of orphan drug designations and approvals. Partial orphan drugs are those drugs having both orphan and non-orphan indications. Orphan drug development faces many challenges since pharmaceutical companies are generally reluctant in undertaking drug development for orphan diseases due to their low market value. Thus, in order to promote orphan drug development, various strategies have been tried like the enactment of specific legislations and providing incentives for the development of orphan drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
